VXL Stock Discussion
Vaxil Bio Ltd. Description
Vaxil Bio Ltd., formerly Emerge Resources Corp., is an immune-oncology biotechnology company. The Company is engaged in research and development of ImMucin vaccine to treat cancer. The Company develops immunotherapies, including neoantigen peptide products, and antibodies to treat cancer and infectious diseases. The Company offers VaxHit platform, which allows for identification, isolation and production of specific antigen-based immunotherapy products. The Company offers its products from VaxHit technology, which uses the signal peptide (SP) domain in selected targets as core antigens. The Company's product, ImMucin, which has received orphan drug status and designed for the treatment of multiple myeloma (MM) cancer. The Company's ImMucin is in Phase I clinical trial to treat antigen specific immunotherapies; SPmAb2 and SPmAb6 are in pre-clinical stage to treat SP specific antibodies, and MTbuVax is in pre-clinical stage to treat anti-infectives.
Industry: Biotechnology
Keywords: Health Medicine Identification Clinic Drug Biotechnology Disease Cancer Therapy Biology Diseases Oncology Clinical Trial Immunology Antigen Immunotherapy Anti Infectives Antibodies Immune System Immunotherapies Infectious Diseases Peptide Antibody Infectious Disease Multiple Myeloma Vaccine
Recent Comments
- TraderMike on Canadian Depositary Receipts
- Cos3 on Canadian Depositary Receipts
- TraderMike on Canadian Depositary Receipts
- TraderMike on Canadian Depositary Receipts
- Cos3 on Canadian Depositary Receipts
From the Blog
Popular Now
Featured Articles